Cisplatin + Durvalumab
Phase 3Active 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Oropharyngeal Cancer
Conditions
Oropharyngeal Cancer
Trial Timeline
Jul 1, 2015 → Dec 1, 2030
NCT ID
NCT04116047About Cisplatin + Durvalumab
Cisplatin + Durvalumab is a phase 3 stage product being developed by AstraZeneca for Oropharyngeal Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT04116047. Target conditions include Oropharyngeal Cancer.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04116047 | Phase 3 | Active |
Competing Products
12 competing products in Oropharyngeal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Phase 1 | 33 |
| Cetuximab + Cisplatin | Eli Lilly | Phase 2 | 52 |
| Durvalumab + Tremelimumab | AstraZeneca | Phase 1/2 | 41 |
| Cisplatin + Durvalumab + Tremelimumab | AstraZeneca | Phase 2 | 52 |
| Chemoradiotherapy arm + Immunotherapy + Radiotherapy arm | AstraZeneca | Phase 2 | 52 |
| MEDI0457 + Durvalumab | AstraZeneca | Phase 2 | 52 |
| VB10.16 + Pembrolizumab | Merck | Phase 1/2 | 41 |
| Cetuximab | Merck | Phase 2 | 52 |
| 9 valent human papillomavirus vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) | Merck | Phase 3 | 77 |
| Paclitaxel + Carboplatin + Nivolumab | Bristol Myers Squibb | Phase 2 | 51 |
| Cyclophosphamide + IRX-2 + Nivolumab | Bristol Myers Squibb | Phase 1 | 32 |
| CUE-101 | Cue Biopharma | Phase 2 | 44 |